INTRODUCTION AND OBJECTIVES:
Up to 10% of cases of Prostate Cancer (PCa) are hereditary. Germline pathogenic mutations in BRCA2 gene confer the highest risk (2.5 to 8.6 fold in men < 65 yr) [1] [2] [3] . Beyond periodic Prostate Specific Antigen (PSA) dosage and digital rectal examination (DRE), a targeted screening for carriers is still undefined. Prostate health index (PHI), a combination of the tPSA, fPSA and proPSA tests, may be a more accurate biomarker than PSA only to detect PCa [4] . We evaluated how to better screen BRCA2 mutated men for PCa.
METHODS: We reviewed the genealogical trees of all women who tested positive for germline BRCA2 pathogenic mutation at our clinic. We offered targeted BRCA2 mutational analysis to all first/second degree relative men between 40 and 69 yr. A targeted screening program (annual PSA and PHI dosages and DRE) was proposed to all men who tested positive. If PSA and/or PHI values were out of range (>4ng/mg and >20, respectively) we proceeded with a multiparametric Magnetic Resonance Imaging (mpMRI) and fusion biopsy of suspected lesions.
RESULTS: From June 2008 to October 2018 610 breast/ ovarian cancer patients underwent BRCA1/2 test: 35 (5.7%) tested positive for BRCA1 pathogenic mutation, 32 (5.2%) for BRCA2 pathogenic mutation. From October 2017 90 relatives were checked for the familial mutation, 23 (26%) (12 women and 11 men) tested positive for BRCA2 pathogenic mutation. All the 11 men (median age 48 yr, IQR 44 to 60) accepted to join our screening program. During the first year all men had negative DRE. Median PSA was 0.54 (IQR 0.43 to 0.98), median PHI was 15.93 (IQR 12.00 to 24.06). One man had PHI out of range and had an mpMRI that resulted negative. During the second year 4 men underwent screening: they had negative DRE. Median PSA was 0.57 (IQR 0.38-0.77), median PHI was 16.88 ). Two men had PHI out of range and underwent mpMRI. Both of them were postive for lesions PIRADS IV and underwent fusion biopsy; one was positive for prostate adenocarcinoma Greason 4þ3.
CONCLUSIONS: An accurate evaluation of the genealogical trees of breast/ovarian cancer BRCA2 mutated patients allows to identify male relatives potentially carriers of the same mutation. These patients have a high lifetime risk of PCa and require an appropriate screening, currently absent. Our approach may be leveraged as proof of concept of selection and subsequent screening program in carriers of BRCA2 mutations. METHODS: 1509 pts were randomized 2:1 to DARO 600 mg (two 300 mg tablets) twice daily (n[955) or PBO (n[554) while continuing androgen deprivation therapy. The primary end point was MFS. Secondary and exploratory endpoints included OS, time to cytotoxic chemotherapy, time to antineoplastic therapy, and safety. Exploratory endpoints included time to PSA progression and QoL, assessed by the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and the European Organisation for Research and Treatment of Cancer QoL Prostate Cancer module (EORTC-QLQ-PR25).
RESULTS: DARO elicited an overall PSA response of !50% in 84% of pts vs 8% with PBO; 51% of pts had !90% PSA decline with DARO. DARO substantially delayed time to PSA progression (33 vs 7 mo; HR 0.13; 95% CI 0.11-0.16; P<0.001), time to cytotoxic chemotherapy (not reached [NR] vs 38 mo; HR 0.43; 95% CI 0.31-0.60; P<0.001), and time to antineoplastic therapy (NR vs NR; HR 0.33; 95% CI 0.23-0.47; P<0.001) compared with PBO. Incidences of Tx-emergent AEs with !5% frequency or grade 3-5 were comparable between study arms; only fatigue had an incidence of >10%. AE-related discontinuation rates were similar between study arms. AEs of interest (including fracture, falls, seizures, weight decrease, hypertension, and cognitive disorder) showed minimal or no difference in incidence between study arms. QoL was similar for DARO and PBO; differences in leastsquares mean time-adjusted area under curve scores for BPI-SF, FACT-P, and EORTC-QLQ-PR25 subscales consistently favored DARO.
CONCLUSIONS: DARO delays disease progression and subsequent Tx for metastatic CRPC compared with PBO, preserving QoL without increasing the prevalence of key AEs.
